Treatment of Fragile X Syndrome with cannabidiol
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
1. A method of treating a human suffering from Fragile X Syndrome comprising administering a therapeutically effective amount of isolated cannabidiol to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.
2. The method of claim 1 , wherein the therapeutically effective amount of isolated cannabidiol is between about 50 mg to 500 mg total daily.
3. The method of claim 2 , wherein the therapeutically effective amount of isolated cannabidiol is 250 mg total daily.
4. The method of claim 2 , wherein the therapeutically effective amount of isolated cannabidiol is 500 mg total daily.
5. The method of any of claim 3 and claim 4 , wherein the isolated cannabidiol is administered in two daily doses.
6. The method of claim 5 , wherein the isolated cannabidiol is (−)-cannabidiol.
7. The method of claim 1 , wherein the isolated cannabidiol is administered transdermally, and is formulated as a permeation-enhanced gel.